Anti-equol Antibody Composition for Sensitive Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-equol antibodies have unsatisfactory cross-reactivity and detection sensitivity, making it difficult to measure equol accurately and with high precision in biological samples.
Innovation Solution
A composition of anti-equol antibodies with specific amino acid sequences in their heavy and light chain variable regions, providing high cross-reactivity to R-equol and S-equol while minimizing cross-reactivity with other compounds, allowing for precise and sensitive equol detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional anti-equol antibodies are used for equol detection, then the detection method is simple, but the cross-reactivity and detection sensitivity are unsatisfactory
Solution Approach 1:
The patent segments the antibody composition into two distinct anti-equol antibodies with different specificities: one antibody specifically recognizes S-equol, while the other recognizes both S-equol and R-equol. This segmentation allows the composition to achieve high detection sensitivity for both equol enantiomers while maintaining a relatively simple overall structure that can be implemented in conventional detection assays.
2Reliability
If conventional anti-equol antibodies are used, then the assay procedure is straightforward, but the cross-reactivity with other isoflavones is high
Solution Approach 1:
The patent applies local quality by endowing each antibody in the composition with distinct binding characteristics: the first antibody is optimized for high specificity to S-equol with minimal cross-reactivity to other isoflavones, while the second antibody provides complementary recognition of R-equol. This localized optimization of binding properties within the composition enables highly specific equol detection without requiring complex procedural modifications.
3Measurement precision
If a single anti-equol antibody is used, then the composition is simple, but the ability to differentiate and quantify R-equol and S-equol is limited
Solution Approach 1:
The patent creates a dynamic antibody composition where two antibodies with different binding specificities work cooperatively: the first antibody provides stable baseline recognition of S-equol, while the second antibody dynamically contributes to recognition of both enantiomers. This dynamic composition enables accurate differentiation and quantification of R-equol and S-equol through their differential binding responses, while the overall structure remains manageable through rational design of the dual-antibody system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody composition enables accurate and sensitive measurement of equol in biological samples, even with low equol content or in small volumes, with high specificity and low cross-reactivity to other isoflavones and compounds.
Implementation Method 1
a anti-equol antibody or antibody fragment thereof comprising, as an immunoglobulin heavy chain variable region, a heavy chain hypervariable region CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, a hypervariable region CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2 and a hypervariable region CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3
Data Source
AI summary
An anti-equol antibody composition, containing an anti-equol antibody or antibody fragment thereof containing, as an immunoglobulin heavy chain variable region, hypervariable regions CDR1, CDR2, and CDR3 respectively including amino acid sequences represented by SEQ ID NO: 1-3, and as an immunoglobulin light chain variable region, hypervariable regions CDR1′, CDR2′, and CDR3′ respectively including amino acid sequences represented by SEQ ID NO: 4-6; and an anti-equol antibody or antibody fragment thereof containing, as an immunoglobulin heavy chain variable region, hypervariable regions CDR1, CDR2, and CDR3 respectively including amino acid sequences represented by SEQ ID NO: 1-3, and as an immunoglobulin light chain variable region, hypervariable regions CDR1′, CDR2′, and CDR3′ respectively including amino acid sequences represented by SEQ ID NO: 7-9.